Correlation of microRNA-372 upregulation with poor prognosis in human glioma.
Correlation of microRNA-372 upregulation with poor prognosis in human glioma.
复制标题
microRNA-372 上调与人类神经胶质瘤预后不良的相关性。
DOI：
10.1186/1746-1596-8-1
复制
发表时间：
2013-01-08
影响因子：
2.6
通讯作者：
Gao G
中科院分区：
文献类型：
--
作者：
Li G;Zhang Z;Tu Y;Jin T;Liang H;Cui G;He S;Gao G
MicroRNA-372 (miR-372) 在多种人类恶性肿瘤中充当致癌 miRNA 或抗癌 miR。然而，其在神经胶质瘤中的作用尚未阐明。为了解决这个问题，我们通过实时定量 RT-PCR 检测检测了人胶质瘤和非肿瘤性脑组织中 miR-372 的表达。还统计分析了miR-372表达与神经胶质瘤患者的临床病理因素或预后的关系。结果，与相应的非肿瘤性脑组织相比，胶质瘤组织中的miR-372表达水平显着上调（P<0.001）。此外，miR-372的高表达与胶质瘤患者的病理分级晚期（P=0.008）和卡氏评分（KPS）低（P=0.01）显着相关。此外，miR-372高表达患者的总生存期明显短于miR-372低表达患者（P<0.001）。此外，多变量Cox回归分析表明miR-372表达是胶质瘤患者的独立预后因素（P=0.008）。更重要的是，根据肿瘤病理分级进行亚组分析发现，病理分级晚期的胶质瘤患者的累积总生存期，miR-372高表达组显着差于miR-372低表达组（P<0.001），而病理分级低的患者则无显着性差异（P=0.08）。总而言之，这些数据首次提供了令人信服的证据，证明 miR-372 可能作为神经胶质瘤中的致癌 miRNA，代表了侵袭性发展的潜在调节因子和这种恶性肿瘤的候选预后标志物，特别是对于病理分级较高的晚期肿瘤。本文的虚拟幻灯片可以在这里找到：http://www.diagnosticpathology.diagnomx.eu/vs/1707761328850011
MicroRNA-372 (miR-372) acts as either an oncogenic miRNA or an anti-oncomiR in various human malignancies. However, its roles in gliomas have not been elucidated. To address this problem, we here detected miR-372 expression in human gliomas and non-neoplastic brain tissues by real-time quantitative RT-PCR assay. The association of miR-372 expression with clinicopathological factors or prognosis of glioma patients was also statistically analyzed. As the results, miR-372 expression levels were significantly upregulated in glioma tissues compared to the corresponding non-neoplastic brain tissues (P<0.001). In addition, the high miR-372 expression was significantly associated with the advanced pathological grade (P=0.008) and the low Karnofsky performance score (KPS) of glioma patients (P=0.01). Moreover, the overall survival of patients with high miR-372 expression was dramatically shorter than those with low miR-372 expression (P<0.001). Furthermore, multivariate Cox regression analysis indicated that miR-372 expression was an independent prognostic factor for glioma patients (P=0.008). More importantly, subgroup analyses according to tumor pathological grade revealed that the cumulative overall survival of glioma patients with advanced pathological grades was significantly worse for high miR-372 expression group than for low miR-372 expression group (P<0.001), but no significant difference was found for patients with low pathological grades (P=0.08). Taken together, these data offer the convincing evidence for the first time that miR-372 may act as an oncogenic miRNA in gliomas and represent a potential regulator of aggressive development and a candidate prognostic marker for this malignancy, especially for advanced tumors with high pathological grades. The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1707761328850011
登录
查看更多内容
影响因子：
2.6
作者：
Gömöri E;Pál J;Kovács B;Dóczi T
通讯作者：
Dóczi T
胶质瘤患者SLC22A18低表达与不良预后的相关性
影响因子：
2
作者：
Chu, Sheng-Hua;Ma, Yan-Bin;Jiang, Pu-Cha
通讯作者：
Jiang, Pu-Cha
影响因子：
3.8
作者：
Cho, Wha Ja;Shin, Jeong Min;Kim, Kye-Seong
通讯作者：
Kim, Kye-Seong
影响因子：
2.6
作者：
Gulati, Sasha;Ytterhus, Borgny;Torp, Sverre H.
通讯作者：
Torp, Sverre H.
影响因子：
2.6
作者：
Wang Q;Deng J;Yuan J;Wang L;Zhao Z;He S;Zhang Y;Tu Y
通讯作者：
Tu Y